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Cardiovascular disease (CVD) is a major public
health problem in industrialized countries. Decades of
research have established major variable risk factors for
the development of CVD, such as smoking, elevated
blood pressure, dyslipidaemia, diabetes mellitus, etc.
Consideration of all these factors together allows the
calculation of individual 10-year absolute cardiovascu-
lar risk scores and the identification of those individu-
als who in priority deserve more rigorous lifestyle and
possibly drug interventions (1). Despite several contro-
versies, lowering low-density lipoprotein (LDL) cho-
lesterol is still the emphasis of the prevention of coro-
nary heart disease (CHD) (1, 2). To achieve the LDL
cholesterol-treatment goals, both diet and drugs, essen-
tially statins, are at the forefront of intervention strate-
gies (3).
The scientific basis for attributing a prominent, but
not exclusive, role of dietary cholesterol and saturated
fat in the genesis of atherosclerosis and ultimately CHD
is buttressed by several lines of evidence that have been
gathered over the past 150 years. These are essentially
animal experiments, epidemiological correlations, and
human nutritional studies. These observations support
the implementation of nutritional approaches to reduce
atherosclerotic CVD. The recent United States National
Cholesterol Education Program Adult Treatment panel
III (NCEP-ATP III) guidelines (2) translate the most re-
cent scientific data into recommendations for healthcare
providers. These include the limitation of fat intake (re-
duced to 25-35 % of calories), saturated fat (7 % of calo-
ries) and dietary cholesterol (less than 200 mg/day), and
the achievement and maintenance of ideal body weight.
These steps are supported by considerable evidence for
efficacy in reducing total and LDL cholesterol levels.
However, the reduction that can be achieved in choles-
terol by diet therapy seems rather small compared with
the marked reduction by lipid-lowering agents. Never-
theless, diet is still important, especially on a popula-
tion basis, but also in high-risk individuals. Indeed, a
lipid-lowering diet can reduce the number of individu-
als requiring drug therapy and diminish the requested
dosage to achieve cholesterol target levels, thus reduc-
ing the overall cost of drug therapy. Meanwhile, it may
result in an added reduction in cholesterol of 5 % be-
yond that attained by drug therapy, which could provide
at least theoretically an additional 5 % reduction in CHD.
 Statins are the most potent cholesterol-lowering
drugs : they inhibit hepatic HMG-CoA reductase, re-
duce liver cholesterol synthesis and overexpress hepa-
tocyte LDL receptors, leading to dose-dependent reduc-
tions in total and LDL cholesterol levels up to 50-60 %
(as compared to a maximum of 10 to 20 % with diet
alone). Statins have proven their efficacy for reducing
CVD events in numerous controlled, randomised clini-
cal trials according to Evidence-Based Medicine (4,5).
Significant LDL cholesterol reductions of 25 % to 35 %
and a decrease in coronary risk of 23 % to 37 % have
justified the use of statins for lipid lowering in conjunc-
tion with diet therapy in high-risk patients (4,5). Fur-
thermore, the latest research demonstrates that statins
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have additional biological effects (so-called pleiotropic
effects) that may partially explain their efficacy in re-
ducing the incidence of CHD beyond what is expected
from cholesterol reduction alone (6). Overall, statins
have potent LDL cholesterol-lowering effects, as well
as favourable effects on multiple nonlipid risk factors
for CHD. This constellation of benefits provides a pow-
erful approach for reducing risk of CHD, even in indi-
viduals with only modest elevations of total and LDL
cholesterol levels, as pointed out by the recent results of
the Heart Protection Study (7). Because of their cost
effectiveness, high compliance rate, and safety when
used appropriately, statins should be considered as the
drugs of choice to treat hypercholesterolaemia in high-
risk CVD-prone patients (1-5).
The survey of Devroey and Willem published in this
issue of the Acta Clinica Belgica (8) aimed at evaluat-
ing the diet-induced changes in fasting lipoprotein lev-
els among patients who wait for the reimbursement of a
lipid-lowering drug according to the Belgian procedure.
Of the patients who finally received lipid-lowering drugs
(because total cholesterol level remained higher than 250
mg/dl or triglycerides remained higher than 200 mg/dl
after 3 months of diet treatment alone), half were not
able to decrease their total cholesterol level with diet
before the initiation of the pharmacological treatment.
However, no information either on precise diet counsel-
ling by the health care provider or on patient’s diet com-
pliance was available in this study. Furthermore, it would
have been interesting to know the lipid changes in pa-
tients (whose proportion is unknown) to whom diet was
initially recommended and for whom a lipid-lowering
drug was finally not prescribed (presumably because diet
was effective enough, at least to decrease the lipid lev-
els below the rather high target levels defined by the
Belgian reimbursement system, i.e. total cholesterol <
250 mg/dl). Finally, the study concerned a mixed popu-
lation including subjects in either primary or secondary
prevention. One can suspect that the rules of diet and
drug prescription may differ between the two subgroups.
On the one hand, patients in secondary prevention may
have a better response to life-style changes than sub-
jects in primary prevention, because of better compli-
ance. On the other hand, physicians may be more moti-
vated to prescribe statins (rather than fibrates) in the
former, very high-risk group because of the well-known
demonstration of cardiovascular protection provided by
this pharmacological class in the last 10 years, espe-
cially in secondary prevention.
The Authors (8) pointed out that cardiovascular risk
factors are still not taken into account for the reimburse-
ment of statins in Belgium. Indeed, the only criterion is
the maintenance of cholesterol levels above 250 mg/dl
after 3 months of diet therapy, whatever the CVD risk
profile. Obviously, Belgian reimbursement criteria are
old fashioned and should be adapted urgently for a more
rationale use of lipid-lowering drugs in daily practice
according to Evidence-Based Medicine (4). Indeed, with
the current procedure, numerous patients at very high
risk, because of previous cardiovascular events (second-
ary prevention) or a high-risk cardiovascular profile (pri-
mary prevention with an estimated score of cardiovas-
cular events above 20 % in the next 10 years), are not in
a position to benefit from statin therapy despite the fact
that statins have extensively proven their efficacy and
cost-effectiveness in such a population. Interestingly
enough, the primary prevention Anglo-Scandinavian
Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-
LLA) was performed in individuals who would not have
benefit from the reimbursement of lipid-lowering agents
according to current Belgian criteria, i.e. hypertensive
patients with at least three other cardiovascular risk fac-
tors, but with total cholesterol concentrations 250 mg/
dl or less (9). Nevertheless, after a median follow-up of
3.3 years, the incidence of non-fatal myocardial infarc-
tion and fatal coronary heart disease was reduced by
36 % in patients treated with atorvastatin as compared
to the placebo group. Moreover, the rule of imposing a
3-month diet therapy in patients with recent cardiovas-
cular event may contribute to delay the prescription of
an active drug and to increase the risk that such a drug
will never be given. Indeed, the EURO-ASPIRE II sur-
vey demonstrated that, among individuals from 15 Eu-
ropean countries, Belgian patients with CHD had the
highest cholesterol level and the lowest rate of statin
therapy at hospital discharge and 1-2 years later, fol-
lowing a serious CHD event (10). In contrast, with the
current Belgian procedure, numerous individuals may
receive a lipid-lowering drug because total cholesterol
levels remain above 250 mg/dl although they are not at
high risk for cardiovascular disease, especially in the
female population. The evidence of any benefit of treat-
ing such subjects with lipid-lowering agents is scarce,
and such inappropriate use of expensive drugs is waste
of money.
Finally, Devroey and Willem made a proposal for
new reimbursement criteria in Belgium (8). The main
difference as compared to the recommendations of the
Second European Joint Task Force (1), endorsed by the
Belgian Lipid Club, is the use of the ratio of total cho-
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lesterol to HDL cholesterol instead of total (or LDL)
cholesterol. Such change is in agreement with the more
recent Joint British recommendations (11), but not with
those of the US NCEP-ATP III (2). Even if the role of
HDL cholesterol should probably be reconsidered, it
seems preferable to wait the new guidelines of the Eu-
ropean Task Force (SCORE) that should be officially
presented and published end 2003. The proposal by
Devroey and Willem still requests a baseline lipid pro-
file and an initial period of lifestyle changes during three
months, even in secondary prevention. This proposal is
questionable in view of the recent positive results of the
Heart Protection Study (7). This study indeed demon-
strated the efficacy of simvastatin in high-risk patients -
because of previous CVD or diabetes mellitus and
microalbuminuria, or hypertension and left ventricular
hypertrophy -, independently of the initial total and LDL
cholesterol level. Similar results were recently reported
in the ASCOT-LLA study (9). Furthermore, evidence
from experimental studies and from at least one
randomised, placebo-controlled clinical trial (12) sup-
ports the use of early and intensive lipid-lowering as
part of the initial medical management of patients with
acute coronary syndrome. Thus, especially in patients
with clinical manifestations of atherosclerosis, current
evidence suggests that statins should be prescribed in-
dependently of prevailing cholesterol level and of any
initial dietary test period. Of course, this does not mean
that lifestyle changes are meaningless to reduce CHD
and that cholesterol check is needless to verify both ef-
ficacy of and compliance to lipid-lowering therapy (13).
In conclusion, a well-balanced optimal use of dietary
and pharmacological approaches is needed to reduce
CVD in a cost-effective manner. Adequate nutritional
advice should be brought to the population at large, while
lipid-lowering agents, in addition to diet, should be rec-
ommended in an individual approach targeting high-risk
patients (1,2). The dynamic duo of diet and lipid-lower-
ing drugs provides the most effective clinical means
identified to date for maximally lowering LDL choles-
terol levels. However, to impose a period of diet therapy
in high-risk patients before reimbursing lipid-lowering
agents represents a risk of postponing the most effec-
tive treatment and sometimes of never using it !
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